Unity Biotechnology, Inc.

NasdaqGS:UBX Stok Raporu

Piyasa değeri: US$22.1m

Unity Biotechnology Temettü

Temettü kriter kontrolleri 0/6

Unity Biotechnology does not have a record of paying a dividend.

Anahtar bilgiler

n/a

Temettü verimi

-20.0%

Geri Alım Getirisi

Toplam Hissedar Getirisi-20.0%
Gelecekteki Temettü Verimi0%
Temettü Büyümesin/a
Bir sonraki temettü ödeme tarihin/a
Eski temettü tarihin/a
Hisse başına temettün/a
Ödeme oranın/a

Son temettü güncellemeleri

Güncelleme yok

Recent updates

Will Unity Biotechnology (NASDAQ:UBX) Spend Its Cash Wisely?

Jul 12
Will Unity Biotechnology (NASDAQ:UBX) Spend Its Cash Wisely?

Here's Why We're A Bit Worried About Unity Biotechnology's (NASDAQ:UBX) Cash Burn Situation

Mar 05
Here's Why We're A Bit Worried About Unity Biotechnology's (NASDAQ:UBX) Cash Burn Situation

Companies Like Unity Biotechnology (NASDAQ:UBX) Could Be Quite Risky

Nov 18
Companies Like Unity Biotechnology (NASDAQ:UBX) Could Be Quite Risky

UNITY Biotechnology falls 7% on reverse stock split

Oct 19

Unity Biotechnology cuts stock sales agreement in half to $25M

Aug 19

Unity Biotechnology GAAP EPS of -$0.19 beats by $0.10, revenue of $0.24M

Aug 12

A Look At Unity's UBX1325 Phase 1 Results

Jul 26

Trade Alert: The Co-Founder Of Unity Biotechnology, Inc. (NASDAQ:UBX), Nathaniel David, Has Sold Some Shares Recently

Dec 22
Trade Alert: The Co-Founder Of Unity Biotechnology, Inc. (NASDAQ:UBX), Nathaniel David, Has Sold Some Shares Recently

A Look Inside Unity Bio's Transition To An Ophthalmology Company

Nov 27

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: Insufficient data to determine if UBX's dividends per share have been stable in the past.

Büyüyen Temettü: Insufficient data to determine if UBX's dividend payments have been increasing.


Piyasaya Karşı Temettü Getirisi

Unity Biotechnology Piyasaya Karşı Temettü Getirisi
UBX temettü verimi piyasa ile karşılaştırıldığında nasıldır?
SegmentTemettü Verimi
Şirket (UBX)n/a
Pazarın Alt %25'i (US)1.5%
Pazarın En İyi %25'i (US)4.5%
Sektör Ortalaması (Biotechs)2.2%
Analist tahmini (UBX) (3 yıla kadar)0%

Önemli Temettü: Unable to evaluate UBX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

Yüksek Temettü: Unable to evaluate UBX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: Insufficient data to calculate UBX's payout ratio to determine if its dividend payments are covered by earnings.


Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: Unable to calculate sustainability of dividends as UBX has not reported any payouts.


Güçlü temettü ödeyen şirketleri keşfedin